“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. Patients who took Ozempic also saw an 18% reduction in nicotine dependence compared ...

It could also play a role in reducing the risk of dementia.We asked the experts. Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 ... The reduction in food preoccupation ...

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests. Researchers found these medications show promise in ...

Ozempic and Wegovy have the same active ingredient, semaglutide, in different doses, and mimic the hormone glucagon-like peptide-1. Released by the gut after eating, GLP-1 travels through the ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million ...